Paradigm Biopharmaceuticals Ltd. (PBIGF)

OTHER OTC:PBIGF

PBIGF

Paradigm Biopharmaceuticals

RESEARCH TOOLSreports

Want to see PBIGF full AI Analyst Report?

Paradigm Biopharmaceuticals (PBIGF) Price & Analysis

17 Followers

PBIGF Stock Chart & Stats

$0.24

-$0.01(-3.72%)

At close: Jan 06 4:00 PM EST

$0.24

-$0.01(-3.72%)

Day’s Range― - ―

52-Week Range$0.12 - $0.35

Previous CloseN/A

Volume2.27K

Average Volume (3M)1.65K

Market Cap

$66.63M

Enterprise Value$67.67M

Total Cash (Recent Filing)$14.66M

Total Debt (Recent Filing)$1.01M

Price to Earnings (P/E)―

Beta-0.31

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding525,456,670

10 Day Avg. Volume200

30 Day Avg. Volume1,650

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)4.53

Price to Sales (P/S)1840.42

P/FCF Ratio-6.00

Enterprise Value/Market Cap1.02

Enterprise Value/Revenue1.12K

Enterprise Value/Gross Profit-693.50

Enterprise Value/Ebitda-1.66

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.07

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet / Low DebtVery low debt reduces refinancing and interest-rate risk and preserves financial optionality over months. For a cash-burning biopharma this conservatism lengthens runway, supports future R&D or commercial investment, and improves negotiating flexibility with partners and lenders.

Narrowed Net Loss And Improved Cash OutflowA materially smaller loss and sharply reduced cash outflow in FY2025 indicate operational progress rather than one-off moves. Sustained reduction in burn improves the company's ability to fund development without immediate large raises, lowering dilution risk and improving chances of reaching self-sustaining cash flow.

Commercialisation And Licensing Revenue ModelA business model combining direct product commercialisation plus potential licensing/distribution deals diversifies revenue pathways. This structural mix allows scaling via partner networks, reduces reliance on a single product launch, and supports steadier long-term revenue capture if approvals and partnerships progress.

Bears Say

Persistent Negative Cash FlowOngoing negative operating and free cash flow means the company remains dependent on external capital to fund operations and development. Over a 2-6 month horizon this continues to raise dilution and refinancing risk, constrains discretionary spending, and limits the ability to scale commercial activities sustainably.

Very Small, Volatile And Declining RevenueLow and unstable revenue prevents achieving operating scale and leaves gross margins exposed to fixed costs. A meaningful FY2025 revenue decline signals fragile commercial traction, increasing execution risk for product rollouts and weakening the base needed to fund ongoing R&D and market expansion.

Equity Erosion And Sustained LossesMaterial decline in equity and persistently negative returns reflect ongoing value erosion from cumulative losses. Over months this undermines balance-sheet resilience, reduces buffers against adverse shocks, and makes future capital raises more dilutive or expensive, constraining strategic flexibility.

Paradigm Biopharmaceuticals News

Paradigm Completes Institutional Placement and Prepares Share Purchase Plan

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an announcement. Paradigm Biopharmaceuticals has completed a placement of 73,684,211 fully...

7d ago

Paradigm Biopharmaceuticals Seeks Quotation for 73.7 Million New Shares on ASX

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals has applied for quotation on the ASX...

7d ago

Paradigm Reshapes Obsidian Funding Terms Around Phase 3 Milestones

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an announcement. Paradigm Biopharmaceuticals has amended its convertible securities and share...

8d ago

Paradigm Biopharmaceuticals Launches $2m Share Purchase Plan After $14m Placement

Paradigm Biopharmaceuticals ( ($AU:PAR) ) just unveiled an announcement. Paradigm Biopharmaceuticals has completed a $14 million placement of...

8d ago

Paradigm Clears Key Safety Milestone and Expands Sites in Phase 3 Osteoarthritis Trial

An update from Paradigm Biopharmaceuticals ( ($AU:PAR) ) is now available. Paradigm Biopharmaceuticals said its pivotal Phase 3...

8d ago

Paradigm’s iPPS Osteoarthritis Data at OARSI Strengthen Case for Phase 3 Program

The latest update is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals reported new mechanistic and clinical...

9d ago

Paradigm Hits 50% Dosing in Global Knee OA Trial and Bolsters Funding

Paradigm Biopharmaceuticals ( ($AU:PAR) ) just unveiled an update. Paradigm Biopharmaceuticals reported continued momentum in its global Phase...

11d ago

Paradigm Biopharmaceuticals Launches Securities Purchase Plan With Options Package

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals has announced a proposed securities purchase plan,...

11d ago

Paradigm Biopharmaceuticals Plans Major Share and Option Issue to Boost Capital

The latest announcement is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals has outlined a proposed capital...

11d ago

Paradigm boosts funding to carry Phase 3 trial through key interim data

An update from Paradigm Biopharmaceuticals ( ($AU:PAR) ) is now available. Paradigm Biopharmaceuticals has completed a significantly upsized...

11d ago

PBIGF FAQ

What was Paradigm Biopharmaceuticals Ltd.’s price range in the past 12 months?

Paradigm Biopharmaceuticals Ltd. lowest stock price was $0.12 and its highest was $0.35 in the past 12 months.

What is Paradigm Biopharmaceuticals Ltd.’s market cap?

Paradigm Biopharmaceuticals Ltd.’s market cap is $66.63M.

When is Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date?

Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 112 days.

How were Paradigm Biopharmaceuticals Ltd.’s earnings last quarter?

Paradigm Biopharmaceuticals Ltd. released its earnings results on Feb 26, 2026. The company reported -$0.041 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.041.

Is Paradigm Biopharmaceuticals Ltd. overvalued?

According to Wall Street analysts Paradigm Biopharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Paradigm Biopharmaceuticals Ltd. pay dividends?

Paradigm Biopharmaceuticals Ltd. does not currently pay dividends.

What is Paradigm Biopharmaceuticals Ltd.’s EPS estimate?

Paradigm Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Paradigm Biopharmaceuticals Ltd. have?

Paradigm Biopharmaceuticals Ltd. has 525,456,670 shares outstanding.

What happened to Paradigm Biopharmaceuticals Ltd.’s price movement after its last earnings report?

Paradigm Biopharmaceuticals Ltd. reported an EPS of -$0.041 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5%.

Which hedge fund is a major shareholder of Paradigm Biopharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in PBIGF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Paradigm Biopharmaceuticals Stock Smart Score

Underperform

Blogger Sentiment

Bullish

PBIGF Sentiment 86%
Sector Average 72%

Technicals

Fundamentals

Return on Equity

-265.55%

Trailing 12-Months

Asset Growth

-29.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.